MoonLake Immunotherapeutics (MLTX)

Price$12.35Cached quoteAs of 2026-09-18 03:02 UTC

AI: Fair-priced

Price checkThe market price looks balanced because cash cushions risk, but approval and sales remain uncertain.

Using roughly 85.1 million shares outstanding, the market values MoonLake’s equity near $1.06 billion. Subtracting $537 million of cash and short-term investments and about $102 million of debt leaves roughly $630 million for the drug pipeline and future business. That is meaningful, but not obviously excessive, for a candidate with positive late-stage results in two diseases. Because there are no sales or earnings to anchor value, today’s price requires approval and worthwhile adoption, yet still discounts substantial failure risk. Fair-priced is the most defensible verdict.

Big pictureMoonLake can fund near-term work, but losses are rising and revenue has not started.

MoonLake produced no revenue in 2025, while its net loss widened to $227.3 million from $118.9 million and operating cash use rose to $196.0 million from $116.6 million. First-half 2026 operating cash use reached $121.8 million, about 31% above the prior-year half. Against that, $537.0 million of cash and short-term investments, $101.5 million of debt, and current assets exceeding twelve times current liabilities provide real protection. At the first-half pace, net liquid resources cover under two years; management’s mid-2028 runway assumes spending and financing remain controlled.

Business strengthStrong late-stage trial results support the drug, while single-product dependence limits resilience.

Sonelokimab met every Week 16 endpoint in the Phase 3 IZAR-1 arthritis trial, and one-year VELA data showed about 67% of treated hidradenitis patients reached a high-response benchmark, with no new safety signal reported. That breadth is the central bull case. The bear case is concentration: MoonLake remains a single-asset company, so one regulatory or commercial setback affects nearly all value. Economics are also shared; the Merck license carries potential milestones up to €307.1 million and low-to-mid-teen royalties on sales. Risk is driven by clinical milestones rather than normal economic cycles.

What could change the storyRegulatory progress could unlock value, while delays or further share sales could erase it.

Management expected to file the hidradenitis application by the end of September, with acceptance and a priority-review decision by late November; filing, acceptance, and approval would reduce the largest valuation discount. The next arthritis trial and longer follow-up must confirm durable benefit. Financing bought time but diluted ownership: reported shares rose from 63.1 million at 2024 year-end to 85.1 million by August 2026. The June sale raised $200 million gross, plus $30 million from the option. Capital is going to trials and launch preparation, not dividends or repurchases. Future cash needs could require more shares or debt.

AI: News

Arthritis trial clears endpointsThe lead drug succeeded in late-stage arthritis testing, but the results did not satisfy elevated market expectations.

On August 10, the Phase 3 IZAR-1 study met its main goal: 42.1% of patients new to biologic treatments achieved at least a 50% improvement in arthritis signs and symptoms at Week 16. Secondary results included 66.5% reaching a 20% improvement and 61% of patients with skin disease reaching near-clearance. No new safety signal emerged. Shares closed 5.1% lower that session. The timing suggests investors wanted clearer superiority, but it does not prove the data caused the move.

Financing extends the runwayA large share sale funded development through major milestones while meaningfully diluting existing owners.

On June 23, MoonLake priced 9 million shares and 1 million warrants that can become shares, generating $200 million gross; underwriters later bought another 1.5 million shares for $30 million gross. The initial deal netted $189.8 million after costs and helped extend the stated cash runway to mid-2028. It also enlarged the ownership base materially. Shares closed 5.7% lower on June 24; the timing is consistent with dilution concern, but does not prove the offering alone drove the decline.

Long-term skin results strengthenOne-year skin-disease results showed durable responses and supported the planned regulatory filing.

Released June 21, pooled Week 52 results showed 67.2% of treated adults reached the higher response threshold, 33.1% reached complete lesion response, and 26.0% reached inflammatory remission. Adolescent interim data showed about 68% reached the higher threshold, with no new safety signal. Shares closed 15.4% higher on June 22. The timing supports a link to improved confidence in durability and the planned filing, although one trading session cannot establish causation.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2021

2022

2023

2024

2025

Free cash flow

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021
Revenue	$0	$0	$0	$0	—
Research & development	$202.9M	$112.8M	$31.8M	$42.0M	—
Operating expenses	$244.8M	$143.1M	$54.1M	$65.1M	—
Operating income	−$244.8M	−$143.1M	−$54.1M	−$65.1M	−$4.6M
EBITDA	−$242.2M	−$141.7M	−$53.8M	−$64.9M	—
Net income	−$227.3M	−$118.9M	−$36.0M	−$50.0M	−$4.5M
Basic EPSper basic share	-$3.53	-$1.89	-$0.73	-$1.70	-$0.31
Diluted EPSper diluted share	-$3.53	-$1.89	-$0.73	-$1.70	-$0.31

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

19.14%of listed shares

BVF INC/IL16M shares · Jun 30, 2026

View holders

Top 20 reported holders of MLTX
Holder	% owned
BVF INC/IL	19.14%16M shares
Deep Track Capital, LP	8.37%7M shares
T. Rowe Price Investment Management, Inc.	5.12%4.28M shares
D. E. Shaw & Co., Inc.	4.03%3.37M shares
Cormorant Asset Management, LP	3.83%3.21M shares
Jupiter Topco LLC	3.69%3.09M shares
Santos da Silva Jorge	≈3.50%2.92M shares
Reich Kristian	≈3.42%2.86M shares
Logos Global Management LP	3.20%2.68M shares
Weiss Asset Management LP	3.09%2.58M shares
CITADEL ADVISORS LLC	2.36%1.97M shares
TWO SIGMA INVESTMENTS, LP	2.05%1.72M shares
MPM BIOIMPACT LLC	1.92%1.61M shares
Vivo Capital, LLC	1.67%1.4M shares
JPMORGAN CHASE & CO	1.66%1.39M shares
Point72 Asset Management, L.P.	1.39%1.16M shares
Bodenstedt Matthias	≈1.33%1.12M shares
BlackRock, Inc.	1.31%1.09M shares
PRICE T ROWE ASSOCIATES INC /MD/	1.25%1.04M shares
Balyasny Asset Management L.P.	1.09%912.72K shares

Percentages use 83.61M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys1$98.8K disclosed value

Sells (SEC code S)29$234.95M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Jun 22, 2026Form 4 · 10b5-1	Bodenstedt MatthiasChief Financial Officer	SellClass A ordinary shares, par value $0.0001 per share	39.1K	$22.04	$862.2K	1.12M
Jun 18, 2026Form 4 · 10b5-1	Bodenstedt MatthiasChief Financial Officer	SellClass A ordinary shares, par value $0.0001 per share	2.8K	$19.60	$54.8K	1.15M
Jun 17, 2026Form 4 · 10b5-1	Bodenstedt MatthiasChief Financial Officer	SellClass A ordinary shares, par value $0.0001 per share	15.1K	$19.68	$296.8K	1.16M
Jun 17, 2026Form 4 · 10b5-1	Reich KristianChief Scientific Officer	SellClass A ordinary shares, par value $0.0001 per share · indirect	50.0K	$19.43	$971.5K	2.82M
Jun 16, 2026Form 4 · 10b5-1	Reich KristianChief Scientific Officer	SellClass A ordinary shares, par value $0.0001 per share · indirect	50.0K	$18.70	$935.0K	2.87M